Navigation Links
FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
Date:11/20/2007

HENDERSON, Nev., Nov. 20 /PRNewswire/ -- FDA spokesman, Brad Swezey, affirmed to the Wall Street Journal (WSJ) yesterday that the FDA had not received any reports of patient injuries or adverse effects related to use of the eyelash product the agency seized last Friday.

According to its November 16, 2007, news release, the FDA seized an eyelash product (not made by Athena Cosmetics) because the agency had concerns that an ingredient in the product, bimatoprost, could possibly have deleterious side effects if it were improperly used in the eye with a medication used to treat glaucoma that also contains bimatoprost. As affirmed by Mr. Swezey in a November 19th WSJ article, the FDA did not seize the eyelash product because the FDA or the company that made the product had received reports of any of the serious side effects listed in the FDA's news release.

The FDA's action has created some public concern about the safety of similar eyelash products sold by Athena Cosmetics, Inc. and other companies. Athena Cosmetics wants to assure its customers that, as confirmed by the FDA for the product it seized, there have been no reports of patient injuries or significant adverse effects from thousands of satisfied RevitaLash(R) customers. To the contrary, only a very small number of RevitaLash(R) consumers have reported minor, temporary side effects such as irritation or redness. In addition, the safety of RevitaLash(R) has been tested in two clinical tests conducted by a reputable research laboratory. No adverse reactions were observed in either clinical study of RevitaLash(R).

RevitaLash(R) was developed by an ophthalmologist, Dr. Michael Brinkenhoff, the founder of Athena Cosmetics. As a practicing physician, Dr. Brinkenhoff formulated RevitaLash(R) with safety as the highest priority. Thousands of happy and satisfied customers have safely used RevitaLash(R) to enhance the beauty of their eyelashes. While Athena Cosmetics is confident that RevitaLash(
'/>"/>

SOURCE Athena Cosmetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
6. OTC Anti-Aging Products: Hype or Hope?
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
11. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)... and MENLO PARK, Calif. , ... Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced ... statements.  The Company recently changed its fiscal year end ... to list its common stock on a national securities ... financial statements as filed with the United States Securities ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... 2007 /PRNewswire-FirstCall/ -- Celgene,Corporation announced that the ... its Data Monitoring Committee's (DMC),review of preliminary ... patients with newly diagnosed multiple myeloma has ... of dexamethasone (Decadron) in,combination with lenalidomide suggests ...
... HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. ... an important,pilot study with a novel synDNA(TM) ... protect against the avian (H5N1),influenza virus. The ... mice treated with the Company's synDNA(TM) vaccine,whereas ...
Cached Medicine Technology:ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus 2
(Date:9/1/2014)... September 01, 2014 An operating theatre ... hospital for performing surgical operations. An operating room comprises ... surgical booms, operating room lights, imaging displays as well ... report by Transparency Market Research, a U.S.-based market research ... reach USD 4.5 billion by 2019. , According ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
(Date:9/1/2014)... The National Association of Hispanic Nurses ... Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, Rn, ... of Nursing. They will be inducted with Immediate Past ... induction we reported last May. , Our three members ... 2014 American Academy of Nursing Policy Conference in Washington, ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on ... gives members access to thousands of professionally designed tattoo ... aims to help both people who plan on getting ... looking for inspiration in creating one of a kind ... by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... , TUESDAY, Jan. 17 (HealthDay News) -- Middle-aged men ... risk for atrial fibrillation later in life, researchers say. ... Americans -- is a heart rhythm disorder that can lead ... a known risk factor for atrial fibrillation. Previous research ...
... Centre today performed a minimally invasive surgical procedure to ... first time in Canada. The procedure can significantly reduce ... their hypertension through drugs. These patients, numbering approximately 250,000 ... heart attacks and stroke, which continues to kill thousands ...
... at Kessler Foundation have documented increased cerebral activation ... retraining using the modified Story Memory Technique (mSMT). ... behavioral interventions can have a positive effect on ... validating the clinical utility of cognitive rehabilitation. According ...
... By Kathleen Doheny HealthDay Reporter , ... that target an aggressive type of breast cancer known ... drug alone, researchers report. The dual-drug approach greatly ... cancer by the time a woman was due to ...
... treatment of large tumors, how effective is adoptive T ... answer this question, Dr. Kathleen Anders and Professor Thomas ... (MDC) Berlin-Buch and researchers of the Beckman Research Institute ... California, USA designed and carried out a study comparing ...
... If organisations want to retain qualified nurses they need to ... three key age groups and build on the strong attachment ... key messages to emerge from a large-scale survey of nurses ... Advanced Nursing . Australian researchers surveyed 900 nurses from ...
Cached Medicine News:Health News:'Upper Normal' Blood Pressure Linked to Heart Risk in Men 2Health News:Canada's first renal denervation procedure to reduce high blood pressure performed today 2Health News:Drug Duo May Help Fight Aggressive Form of Breast Cancer 2Health News:Drug Duo May Help Fight Aggressive Form of Breast Cancer 3Health News:How immune cells destroy cancer cells - MDC researchers elucidate mechanism 2Health News:Retention study identifies key factors affecting 3 generations of nurses 2Health News:Retention study identifies key factors affecting 3 generations of nurses 3
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: